Advertisement
Singapore markets open in 1 hour 30 minutes

  • Straits Times Index

    3,300.04
    -3.15 (-0.10%)
     

  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     

  • Dow

    38,884.26
    +31.99 (+0.08%)
     

  • Nasdaq

    16,332.56
    -16.69 (-0.10%)
     

  • Bitcoin USD

    62,323.74
    -1,058.48 (-1.67%)
     

  • CMC Crypto 200

    1,294.83
    -70.30 (-5.15%)
     

  • FTSE 100

    8,313.67
    +100.18 (+1.22%)
     

  • Gold

    2,322.90
    -1.30 (-0.06%)
     

  • Crude Oil

    78.32
    -0.06 (-0.08%)
     

  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     

  • Nikkei

    38,835.10
    +599.03 (+1.57%)
     

  • Hang Seng

    18,479.37
    -98.93 (-0.53%)
     

  • FTSE Bursa Malaysia

    1,605.68
    +8.29 (+0.52%)
     

  • Jakarta Composite Index

    7,123.61
    -7,135.89 (-50.04%)
     

  • PSE Index

    6,618.58
    -33.91 (-0.51%)
     

Vistin Pharma ASA (VISTN) acquires minority share in CF Pharma (Hungary)

Vistin Pharma ASA
·1-min read
Vistin Pharma ASA
Vistin Pharma ASA

Oslo, Norway, 4 March 2024

Vistin Pharma has aquired a 15% share in CF Pharma Kft. CF Pharma is an API CDMO located in Budapest, Hungary with a broad customer base of recognized international pharmaceutical companies. CF Pharma has a proven track record in developing and commercializing Active Pharmaceutical Ingredients (APIs). The group/company currently has five commercial APIs on the market, with another eight APIs under development.

The transaction price consists of a base price and an earn-out- element, with an agreed cap of MEUR 1.6.

“We have had positive discussions with CF Pharma management and the majority shareholders for some time, to evaluate different partnership models. I am very pleased to announce that Vistin Pharma now has acquired a minority stake in CF Pharma. We see this as a first agreed step in a potential closer partnership in the future, which can broaden our product portfolio and form an important basis for future growth. The cooperation with CF Pharma is a first move in order for Vistin Pharma to execute on the strategy to become a multi-product European API Contract Development and Manufacturing Organization (API CDMO)”, says Magnus Tolleshaug, CEO in Vistin Pharma."

ADVERTISEMENT


For further information, please contact:

Magnus Tolleshaug
CEO
+47 48 40 52 46
magnus.tolleshaug@vistin.com

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.